开角型青光眼：治疗

In open-angle glaucoma, the trabecular meshwork becomes stiff, impeding aqueous humor outflow from the anterior chamber. This blockage causes aqueous humor to accumulate, leading to elevated intraocular pressure. Unlike angle-closure glaucoma, the iridocorneal angle remains open, but the compromised meshwork function prevents normal fluid drainage.

Adrenergic drugs reduce aqueous humor secretion by acting on ciliary body receptors. Brimonidine binds to α2-adrenergic receptors, while timolol binds to both β1 and β2 receptors on ciliary epithelium. These adrenergic antagonists and receptor blockers lower intraocular pressure by decreasing the production of aqueous humor.

Carbonic anhydrase inhibitors like brinzolamide decrease aqueous humor secretion by blocking the enzyme responsible for fluid production in the ciliary body. These drugs are administered topically as eye drops and effectively lower intraocular pressure by reducing the volume of aqueous humor generated.

Cholinomimetic drugs such as pilocarpine bind to muscarinic receptors on the ciliary muscle, stimulating muscle contraction. This contraction opens the trabecular meshwork spaces, enhancing aqueous humor outflow and lowering intraocular pressure. These drugs work through a different mechanism than secretion-reducing agents.

Rho kinase inhibitors and prostaglandins enhance aqueous humor outflow through the trabecular meshwork and uveoscleral pathways, reducing intraocular pressure. Both drug classes improve drainage efficiency rather than decreasing fluid production, offering alternative mechanisms to adrenergic or cholinomimetic agents for managing elevated pressure.

Open-angle glaucoma drugs cause various side effects: brimonidine causes sleepiness, timolol may lead to bronchoconstriction, and pilocarpine weakens vision. Brinzolamide causes burning, netarsudil causes blurriness, and latanoprost changes iris pigmentation. These topical eye drops require careful monitoring for adverse effects during treatment.

Topical eye drops deliver medications directly to the ciliary body and trabecular meshwork, maximizing local therapeutic effects while minimizing systemic absorption. This route allows effective intraocular pressure reduction with lower doses and reduced systemic side effects compared to oral or injectable administration methods.